---
title: 'Not Seeing The Job You''re Looking For? at SpringWorks Therapeutics'
canonical: 'https://feeny.ai/job/not-seeing-the-job-you-re-looking-for-springworks-therapeutics-remote-zcmj6rhp1fv6'
type: 'job'
last_seen: '2026-10-18'
---

# Not Seeing The Job You're Looking For? at SpringWorks Therapeutics

- **Company:** SpringWorks Therapeutics
- **Location:** Remote
- **Work type:** remote
- **Posted:** 2022-10-19
- **Last confirmed live:** 2026-10-18
- **Apply:** https://springworkstx.com/careers/view-opportunities/?gh_jid=4710620004

## Job description

About SpringWorks Therapeutics:

SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany, is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors.

We developed and are commercializing the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN).

At SpringWorks, we are committed to finding answers people with rare tumors need. We thrive in an atmosphere of passion and tenacity, fueled by the excitement of the possibilities science may unlock and driven to work with urgency because of the importance of our work. We value authenticity because diverse backgrounds, cultures, styles and abilities can only help us find the answers that people with rare tumors are looking for.

Not seeing the job you're looking for? Share your resume here and we will contact you when a position becomes available.

We offer best-in-class benefits for our team of SpringWorkers who work with urgency on behalf of patients suffering from devastating diseases. Interested in learning more, review additional information here [Benefits](https://springworkstx.com/careers/benefits/).

EEO Statement: SpringWorks maintains an EEO Policy providing for equitable opportunities for employment and conditions of employment to all employees and applicants regardless of actual or perceived sex (including pregnancy, childbirth, breastfeeding or related medical conditions), gender, gender identity or gender expression, sexual orientation, partnership status, marital status, familial status, pregnancy status, race, color, national origin, ancestry, caste, religion, religious creed, age, alienage or citizenship status, veteran status, military status, physical or mental disability, past or present history of mental disorder, medical condition, AIDS/HIV status, sickle cell or hemoglobin C trait, genetic predisposition, genetic information, protected medical leaves, victims of domestic violence, stalking, or sex offense, political affiliation and any and all other characteristics or categories protected by applicable federal, state or local laws. SpringWorks treats all employees and applicants fairly in the selection process (and in other personnel activities) by giving all employees and applicants the same opportunities for employment. SpringWorks’ Equal Employment Opportunity Policy is intended to ensure that there are no barriers that would prevent members of a protected group from a fair and equitable opportunity to be hired, promoted, or to otherwise take advantage of employment opportunities.

This Equal Employment Opportunity Policy applies to all aspects of employment, including, without limitation, recruitment, hiring, placement, job assignment, promotion, termination, transfer, leaves of absence, compensation, discipline, and access to benefits and training. Any violation of this Policy will result in disciplinary action up to and including termination of employment.

Privacy: Upon submission of this form I understand that SpringWorks Therapeutics is based in the United States and personal data submitted in the form will be transferred and accessed in the U.S.. Information about SpringWorks Therapeutics’ privacy practices can be found at https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fspringworkstx.com%2fprivacy-policy%2f&c=E,1,BD35FHgy1RxvzeWax2mV0qEVg3OfnWVnH9UAE_kbR4Qxe6-WmuH6GscSqesgEvL7QgHjcDXo0uWQw6MBxJlqRq-wDoY16zjPmHPK8_nUDRgAPA,,&typo=1[springworkstx.com](https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fspringworkstx.com&c=E,1,6BmxztI3ctECzNQOe0UHV03yZx9j-Yq5R4PdnIqHiqfxyIU-FpKGq0H-mC5XKvYyi0lXTCDw1loelZS00J9qTEoJQkWo0eiczLkTiNiTUDACDyt_&typo=1&ancr_add=1)).

## About SpringWorks Therapeutics

## Company Overview
- **One-liner**: SpringWorks Therapeutics is a commercial-stage biopharmaceutical company dedicated to unlocking the full potential of targeted oncology for patients with rare tumors.
- **Entity Type**: Public (NASDAQ: SWTX) – acquired by Merck KGaA, Darmstadt, Germany, in April 2025 for $3.9B
- **Headquarters**: Stamford, Connecticut, United States
- **Founded**: 2017
- **Founders**: Not publicly available (spun out from Pfizer in 2017)

## Core Business
- **Primary industry/industries**: Biotechnology – targeted oncology, rare diseases
- **Target customers**: B2B (healthcare providers, hospitals, academic centers) and B2C (patients, patient advocacy groups)
- **Mission or purpose statement**: “Improving the lives of patients with rare tumors” by waging science with tenacity and urgency [springworkstx.com](https://springworkstx.com/who-we-are/)

## Products & Services
- **OGSIVEO® (nirogacestat)**: First and only FDA- and EC-approved gamma secretase inhibitor for adults with progressing desmoid tumors. Also being studied in multiple myeloma, ovarian granulosa cell tumors, and pediatric desmoid tumors. [springworkstx.com](https://springworkstx.com/pipeline/)
- **EZMEKLY® (mirdametinib)**: First and only FDA- and EC-approved MEK inhibitor for adult and pediatric patients (2 years+) with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). Also in Phase 2 for pediatric low-grade gliomas. [springworkstx.com](https://springworkstx.com/pipeline/)
- **SW-682 (TEAD inhibitor)**: Novel small molecule in preclinical development for biomarker-defined solid tumors driven by Hippo pathway mutations. [springworkstx.com](https://springworkstx.com/pipeline/)
- **SW-3431 (PP2A activator)**: First-in-class small molecule activator of specific PP2A complexes in preclinical development for rare uterine cancers. [springworkstx.com](https://springworkstx.com/pipeline/)

## Market Standing
- **Valuation/Market Cap**: $2.3B (as of acquisition by Merck KGaA on April 28, 2025, for $3.9B) [linkedin.com](https://www.linkedin.com/company/springworks-therapeutics)
- **Key Metric**: Annual Revenue $191.6M (2024) / Total Funding raised $1.015B (including Series A, B, and post-IPO equity) [linkedin.com](https://www.linkedin.com/company/springworks-therapeutics)
- **Notable Investors/Partners**: Perceptive Advisors (led Series B), GSK, Janssen, Pfizer, Regeneron (collaborations), Children’s Oncology Group, St. Jude Children’s Research Hospital [springworkstx.com](https://springworkstx.com/pipeline/)
- **Growth Signals**: Two approved products in both U.S. and EU; commercial-stage with $191.6M revenue; 302 employees (down 2.8% YoY due to acquisition integration); operating in 5 countries (U.S., Germany, Switzerland, Italy, UK); pipeline of 4+ programs in Phase 1/2 and preclinical [linkedin.com](https://www.linkedin.com/company/springworks-therapeutics)

## Competitive Advantages
- **First-to-market in rare tumor niches**: Only approved therapy for desmoid tumors (OGSIVEO) and first approved for NF1-PN in both adults and children (EZMEKLY).
- **Deep pipeline of targeted therapies** covering both rare and genetically defined cancers, with multiple collaborations with top pharma and academic centers.
- **Parent company support**: Now part of Merck KGaA, providing global commercial infrastructure, R&D resources, and financial stability.
- **Tenacious culture**: Emphasizes “Care Hard, Ambition Without Ego, Think Deeply Act Quickly, Good Enough is Never Enough, In It Together” – a strong, mission-driven ethos [springworkstx.com](https://springworkstx.com/careers/).

## Strategic Focus
- **Continue to maximize OGSIVEO and EZMEKLY** in existing and new geographies (EU approval just granted in 2025).
- **Expand pipeline into earlier-stage, biomarker-defined cancers** (Hippo mutant tumors, PP2A-driven uterine cancers) and combination therapies (BCMA-targeting agents in multiple myeloma).
- **Leverage Merck KGaA’s global reach** to accelerate clinical development and commercialization of pipeline assets.
- **Invest in pediatric indications** (desmoid tumors, low-grade gliomas) to address high unmet need.

## Why Work Here
- **Mission-driven impact**: Directly improve lives of patients with rare tumors – “Change the lives of patients” and “Help launch groundbreaking therapies” are core promises [springworkstx.com](https://springworkstx.com/careers/).
- **Culture of tenacity and collaboration**: Values include “Care Hard” and “Ambition Without Ego” – fosters a supportive, high-expectation environment.
- **Diversity & inclusion**: Employee Resource Groups (ERGs) actively promote belonging; DEI is integral to the company’s DNA [springworkstx.com](https://springworkstx.com/careers/).
- **Professional growth**: Stretch opportunities, mentorship from smart colleagues, and a chance to help build a company within a larger global pharma (Merck KGaA).
- **Benefits**: Competitive compensation, benefits, and the chance to work on therapies that are first-in-class or best-in-class.
- **Work policy**: Not explicitly stated, but the company has offices in Stamford, CT, and roles across the U.S. and Europe; likely hybrid/office for commercial and lab roles.
- **Headcount**: ~302 employees; recently acquired by Merck, so stability is high but integration may bring changes.

## Sources
1. [springworkstx.com](https://springworkstx.com/) – Company overview, pipeline, news
2. [springworkstx.com](https://springworkstx.com/who-we-are/) – About Us, mission, values
3. [springworkstx.com](https://springworkstx.com/careers/) – Careers page, culture, benefits
4. [springworkstx.com](https://springworkstx.com/pipeline/) – Pipeline details, collaborations
5. [linkedin.com](https://www.linkedin.com/company/springworks-therapeutics) – Employee count, revenue, funding, market cap, acquisition details

## Other roles at SpringWorks Therapeutics

- [Territory Business Manager - New Orleans (GOMEKLI)](https://feeny.ai/job/territory-business-manager-new-orleans-gomekli-springworks-therapeutics-new-4xt5khg55tvb) — / New Orleans, LA
- [Regional Business Director –West Region (OGSIVEO)](https://feeny.ai/job/regional-business-director-west-region-ogsiveo-springworks-therapeutics-9rkhgk4txvxs) — /, United States
- [Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO)](https://feeny.ai/job/associate-director-payer-access-marketing-us-rare-tumors-ogsiveo-springworks-vzwx5gd3w9jp) — / Boston MA, United States
- [Vice President, US Marketing](https://feeny.ai/job/vice-president-us-marketing-springworks-therapeutics-boston-ma-qzb38343hnwm) — / Boston MA, United States
- [Senior Director, Digital & Omnichannel Strategy](https://feeny.ai/job/senior-director-digital-omnichannel-strategy-springworks-therapeutics-boston-ma-jm6szee7haev) — / Boston MA, United States
- [Medical Science Liaison / Senior Medical Science Liaison – West Region](https://feeny.ai/job/medical-science-liaison-senior-medical-science-liaison-west-region-springworks-weh7jdhgqmtc) — /, United States